View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
October 26, 2021updated 04 Jan 2022 9:58am

Q3 2021 saw a 20% rise in new pipeline medical devices globally

By Carmen

The number of new pipeline medical devices at the early development or pre-clinical stage in Q3 2021 saw a 38% increase globally when compared with Q2 2021, according to GlobalData’s pipeline products database.

Compared with Q2 2021, the number of new medical devices in the pipeline in Q3 2021 saw a 20% increase globally.

The global medical devices market was worth $519.39bn in 2021 and is expected to reach $531.77bn by 2023, according to GlobalData’s analysis.


Medical devices pipeline products by market: Healthcare IT has the most devices

Looking at the newly announced pipeline products by market types, Healthcare IT accounted for the largest proportion (24%) in Q3 2021, followed by In Vitro Diagnostics (19%) and Cardiovascular Devices (13%).


North America tops new pipeline products activity

Comparing new pipeline medical device activity in different regions of the globe, North America held the top position (48%) in Q3 2021, followed by Asia-Pacific(28%), and Europe (20%).

At the country level, the US had the most newly announced medical device pipeline products during the quarter, representing the largest share (50%) of the global market. In second place was China (18%), followed by Japan (5%).


New pipeline medical devices: Expected to be approved by 2025

According to GlobalData, in Q3 2021, approximately 53% of newly announced pipeline medical devices are expected to receive regulatory approval by the end of 2025. The leading category for devices expected to receive regulatory approval by the end of 2025 are Disease Specific Immunochemistry, at 0.98% of devices.


Looking at the share of activity among the new pipeline products, developers, private and public company-developed pipeline products accounted for an 84% share of the global medical devices market, while institute-developed pipeline products held the remaining share.

The quarterly average for Q3 2021 saw company-developed new pipeline products accounting for 84% of new pipeline products and institute-developed pipeline products accounting for 16%.


Methodology
The medical devices pipeline data used in this article were extracted from Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database covers all medical devices which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Pipeline products are covered from various authenticated sources like company websites, SEC filings, conference presentations, analyst presentations, news releases, grants etc. The information is collected by following systematic research techniques and proprietary methodology.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU